LCTX

#2830
Lineage Cell Therapeutics, Inc. Common Stock
1.3 4 USD
+9900.00%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
1.34
1.35
Годовой диапазон
0.01
1.98
Дневное изменение
+9900.00%
Месячное изменение
-10.65%
6-месячное изменение
-21.96%
Годовое изменение
-21.96%
Предыдущее закрытие
0.0 1
Open
1.3 5
Low
1.3 4
High
1.3 5
Volume
19
Открыть полный график Full chart

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 334.06 M
  • Employee 77
  • Founded 1990
  • CEO N/A
  • Website www.lineagecell.com
  • Headquarter California, United States
  • FIGI BBG000G8RJY6
  • Industry Биотехнологии
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
-5.96
Коэффициент цена/денежный поток
26.4

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.

Новости